What is the pharmaceutical industry's approach to addressing childhood obesity in America?

Pharmaceutical companies are currently petitioning the FDA to expand GLP-1 drug indications for children under 12 and working with Congress to secure Medicare and Medicaid coverage for pediatric weight-loss treatments. This represents their primary solution to America's childhood obesity crisis - prescribing medication rather than addressing underlying causes. The speaker expresses concern about this medicalized approach, suggesting it may be excessive to put young children on weight-loss drugs as the primary intervention for obesity.